Clinical Trials
16 trialsNCT03132922 2026-06-04
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
Phase 1 Active not recruiting
NCT05492682 2026-05-12
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Valo Therapeutics Oy
Phase 1 Recruiting
NCT03967223 2026-04-17
IGNYTE-ESO
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT04044768 2026-02-06
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT05120271 2025-12-05
DUET-1
Sotio Biotech Inc.
Phase 1/2 Active not recruiting
NCT06644755 2025-07-24
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Recruiting
NCT06748872 2024-12-27
EPITOME-1015-I
Medigene AG
Phase 1 Not yet recruiting
NCT04526509 2024-11-26
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
Adaptimmune
Phase 1 Terminated
NCT05943990 2024-11-13
Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Adaptimmune
Phase 1 Terminated
NCT06048705 2024-11-13
Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer
Adaptimmune
Phase 1 Terminated
NCT03600649 2023-11-21
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Salarius Pharmaceuticals, LLC
Phase 1 Unknown
NCT05266196 2023-08-01
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
Salarius Pharmaceuticals, LLC
Phase 1/2 Unknown
NCT02992743 2023-04-11
Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma
GlaxoSmithKline
Phase 2 Completed
NCT02609984 2020-07-07
IMDZ-C232
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Terminated
NCT00579501 2014-05-07
Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00633165 2010-02-26
SMI-BRS-202
Systems Medicine LLC
Phase 2 Unknown